JP7497300B2 - 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物 - Google Patents

酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物 Download PDF

Info

Publication number
JP7497300B2
JP7497300B2 JP2020565415A JP2020565415A JP7497300B2 JP 7497300 B2 JP7497300 B2 JP 7497300B2 JP 2020565415 A JP2020565415 A JP 2020565415A JP 2020565415 A JP2020565415 A JP 2020565415A JP 7497300 B2 JP7497300 B2 JP 7497300B2
Authority
JP
Japan
Prior art keywords
composition
sodium phosphate
sucrose
oliprodase
methionine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020565415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525083A5 (cg-RX-API-DMAC10.html
JP2021525083A (ja
Inventor
マーク・ヤン
クラウディア・ブサー
ベルナルド・ペレス-ラミレス
グランド・トリエーウェイラー
サンジータ・ベンジャワル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2021525083A publication Critical patent/JP2021525083A/ja
Publication of JP2021525083A5 publication Critical patent/JP2021525083A5/ja
Priority to JP2024039768A priority Critical patent/JP7832245B2/ja
Application granted granted Critical
Publication of JP7497300B2 publication Critical patent/JP7497300B2/ja
Priority to JP2026033801A priority patent/JP2026086903A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2020565415A 2018-05-25 2019-05-24 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物 Active JP7497300B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024039768A JP7832245B2 (ja) 2018-05-25 2024-03-14 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2026033801A JP2026086903A (ja) 2018-05-25 2026-03-04 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676525P 2018-05-25 2018-05-25
US62/676,525 2018-05-25
PCT/US2019/033983 WO2019227029A1 (en) 2018-05-25 2019-05-24 Pharmaceutical compositions for treating acid sphingomyelinase deficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024039768A Division JP7832245B2 (ja) 2018-05-25 2024-03-14 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物

Publications (3)

Publication Number Publication Date
JP2021525083A JP2021525083A (ja) 2021-09-24
JP2021525083A5 JP2021525083A5 (cg-RX-API-DMAC10.html) 2022-05-26
JP7497300B2 true JP7497300B2 (ja) 2024-06-10

Family

ID=66912954

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020565415A Active JP7497300B2 (ja) 2018-05-25 2019-05-24 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2024039768A Active JP7832245B2 (ja) 2018-05-25 2024-03-14 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2026033801A Pending JP2026086903A (ja) 2018-05-25 2026-03-04 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024039768A Active JP7832245B2 (ja) 2018-05-25 2024-03-14 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
JP2026033801A Pending JP2026086903A (ja) 2018-05-25 2026-03-04 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物

Country Status (15)

Country Link
US (1) US20210145941A1 (cg-RX-API-DMAC10.html)
EP (1) EP3802805A1 (cg-RX-API-DMAC10.html)
JP (3) JP7497300B2 (cg-RX-API-DMAC10.html)
KR (1) KR102852946B1 (cg-RX-API-DMAC10.html)
CN (1) CN112424347A (cg-RX-API-DMAC10.html)
AU (2) AU2019275109C1 (cg-RX-API-DMAC10.html)
BR (1) BR112020023829A2 (cg-RX-API-DMAC10.html)
CA (1) CA3101688A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020014399A2 (cg-RX-API-DMAC10.html)
IL (1) IL278964A (cg-RX-API-DMAC10.html)
MX (2) MX2020012700A (cg-RX-API-DMAC10.html)
PY (1) PY1939780A (cg-RX-API-DMAC10.html)
SG (1) SG11202011488WA (cg-RX-API-DMAC10.html)
UY (1) UY38238A (cg-RX-API-DMAC10.html)
WO (1) WO2019227029A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022214529A1 (en) * 2021-02-01 2023-08-03 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of niemann pick type a disease
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514777A (ja) 2003-06-20 2009-04-09 アレス トレーディング ソシエテ アノニム 凍結乾燥fsh/lh製剤
JP2009525963A (ja) 2006-01-20 2009-07-16 ジェンザイム・コーポレーション リソソーム蓄積症のための脳室内酵素の輸送
JP2009526080A (ja) 2006-02-07 2009-07-16 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
JP2013530988A (ja) 2010-06-25 2013-08-01 シャイアー ヒューマン ジェネティック セラピーズ, インコーポレイテッド ヘパランn−スルファターゼのcns送達のための方法および組成物
JP2016088897A (ja) 2014-11-06 2016-05-23 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
WO2017149199A1 (en) 2016-02-29 2017-09-08 Faron Pharmaceuticals Oy A lyophilised pharmaceutical formulation and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
CN1897957A (zh) * 2003-11-25 2007-01-17 纽约大学西奈山医学院 尼曼-皮克病的基于陪伴分子的治疗
BRPI0708879A2 (pt) * 2006-03-13 2011-06-14 Encysive Pharmaceuticals peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
AU2007226582B2 (en) * 2006-03-13 2012-07-05 Revvity Health Sciences, Inc. Substrates and internal standards for mass spectroscopy detection
CA2773133A1 (en) 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
MX338436B (es) 2011-03-31 2016-04-18 Medy Tox Inc Preparacion liofilizada de toxinas de botulismo.
PL3672622T3 (pl) * 2017-08-24 2024-04-02 Genzyme Corporation Rekombinowana ludzka kwaśna sfingomielinaza do zastosowania w leczeniu nieprawidłowych stanów kości u pacjentów z niedoborem kwaśnej sfingomielinazy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514777A (ja) 2003-06-20 2009-04-09 アレス トレーディング ソシエテ アノニム 凍結乾燥fsh/lh製剤
JP2009525963A (ja) 2006-01-20 2009-07-16 ジェンザイム・コーポレーション リソソーム蓄積症のための脳室内酵素の輸送
JP2009526080A (ja) 2006-02-07 2009-07-16 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 遊離チオール部分を有するタンパク質の安定化された組成物
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
JP2013530988A (ja) 2010-06-25 2013-08-01 シャイアー ヒューマン ジェネティック セラピーズ, インコーポレイテッド ヘパランn−スルファターゼのcns送達のための方法および組成物
JP2016088897A (ja) 2014-11-06 2016-05-23 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
WO2017149199A1 (en) 2016-02-29 2017-09-08 Faron Pharmaceuticals Oy A lyophilised pharmaceutical formulation and its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Genetics and Metabolism,2015年,Vol.114,pp.217-225

Also Published As

Publication number Publication date
SG11202011488WA (en) 2020-12-30
KR102852946B1 (ko) 2025-09-02
CO2020014399A2 (es) 2020-12-10
AU2019275109B2 (en) 2025-04-17
WO2019227029A1 (en) 2019-11-28
AU2025205577A1 (en) 2025-08-07
US20210145941A1 (en) 2021-05-20
KR20210015903A (ko) 2021-02-10
UY38238A (es) 2019-12-31
AU2019275109A1 (en) 2021-01-21
MX2020012700A (es) 2021-04-28
CA3101688A1 (en) 2019-11-28
JP2024069459A (ja) 2024-05-21
MX2025002733A (es) 2025-04-02
JP2026086903A (ja) 2026-05-26
AU2019275109C1 (en) 2025-11-13
IL278964A (en) 2021-01-31
CN112424347A (zh) 2021-02-26
JP7832245B2 (ja) 2026-03-17
JP2021525083A (ja) 2021-09-24
EP3802805A1 (en) 2021-04-14
PY1939780A (es) 2019-12-04
BR112020023829A2 (pt) 2021-05-11

Similar Documents

Publication Publication Date Title
US20250073306A1 (en) Formula of neuregulin preparation
RU2640922C1 (ru) Лиофилизированный препарат ботулотоксина
ES2706296T3 (es) Formulaciones de Factor VIII
KR101953494B1 (ko) 동결건조된 재조합 vwf 제제
JP7832245B2 (ja) 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
US12577297B2 (en) Anti-IL-23p19 antibody formulations
KR20140005842A (ko) 헤파란 n-설파타제의 cns 전달을 위한 방법들 및 조성물들
US10918698B2 (en) Lyophilized pharmaceutical composition of Fc-peptide fusion protein
AU2017225236B2 (en) A lyophilised pharmaceutical formulation and its use
US20220080033A1 (en) A lyophilized composition of pegaspargase
RU2826120C2 (ru) Фармацевтические композиции для лечения недостаточности кислой сфингомиелиназы
KR20060108040A (ko) 인 과립구 콜로니 자극인자 용액 제형

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240321

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240529

R150 Certificate of patent or registration of utility model

Ref document number: 7497300

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150